



## Second Sight to Present at September Investor Conferences

August 28, 2019

LOS ANGELES--(BUSINESS WIRE)--Aug. 28, 2019-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics today announced that Will McGuire, President and Chief Executive Officer, and John Blake, Chief Financial Officer, are scheduled to present at three upcoming conferences as follows:

Conference 2019 Wells Fargo Healthcare Conference

Date: Wednesday, September 4, 2019

Time: 3:00 P.M. Eastern Daylight Time

Location: Westin Copley Place, Boston, MA

Webcast: [https://cc.talkpoint.com/well001/090419a\\_js/?entity=79\\_DOKDK3H](https://cc.talkpoint.com/well001/090419a_js/?entity=79_DOKDK3H)

Presenter: Will McGuire, Chief Executive Officer

The Wells Fargo presentation will be webcast live at the aforementioned time and will be archived for 30 days thereafter, via the Company's website at [www.secondsight.com](http://www.secondsight.com), under the Investors Section.

Conference 4<sup>th</sup> Annual Dougherty & Company Institutional Investor Conference

Date: Thursday, September 5, 2019

Location: Millennium Hotel, Minneapolis, MN

Event format: 1x1 meetings

Presenter: John Blake, Chief Financial Officer

Conference H.C. Wainwright 21<sup>st</sup> Annual Global Investment Conference

Date: Monday, September 9, 2019

Time: 2:10 P.M. Eastern Daylight Time

Location: Lotte New York Palace Hotel, New York, NY

Presenter: Will McGuire, Chief Executive Officer

To schedule a one-on-one meeting with management, please contact your H.C. Wainwright or Dougherty & Company representatives, or Greg Falesnik at [greg.falesnik@mzgroup.us](mailto:greg.falesnik@mzgroup.us) and/or Lisa Wilson at [lwilson@insitecony.com](mailto:lwilson@insitecony.com).

### About Second Sight

Second Sight Medical Products, Inc. (NASDAQ:EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company's U.S. headquarters are in Los Angeles, California, and European headquarters are in Lausanne, Switzerland. More information is available at [www.secondsight.com](http://www.secondsight.com).

### About the Orion Visual Cortical Prosthesis System

Leveraging Second Sight's 20 years of experience in neuromodulation for vision, the Orion<sup>®</sup> Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma,

diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain's visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system. Initial results from the Company's Early Feasibility Study support advancement of Orion toward next-stage clinical studies and future commercialization as an FDA designated Breakthrough Device.

#### **Safe Harbor**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," "strategy," "goal," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, our refinement of strategy, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in or implied by the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K, filed on March 19, 2019, our Form 10-Q to be filed on August 6, 2019, and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190828005154/en/>

Source: Second Sight Medical Products, Inc.

#### **Investor Relations:**

Institutional Investors  
In-Site Communications, Inc.  
Lisa Wilson, President  
212-452-2793  
[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

or

Individual Investors  
MZ North America  
Greg Falesnik, Managing Director  
949-385-6449  
[greg.falesnik@mzgroup.us](mailto:greg.falesnik@mzgroup.us)

#### **Media:**

Nobles Global Communications  
Laura Nobles or Helen Shik  
617-510-4373  
[Laura@noblesgc.com](mailto:Laura@noblesgc.com)  
[Helen@noblesgc.com](mailto:Helen@noblesgc.com)